Sign up
Log in
Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday
Share
Listen to the news

U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Monday.

Shares of Kyverna Therapeutics Inc (NASDAQ:KYTX) rose sharply during Monday's session after the company announced topline data from KYSA-8.

The clinical-stage biopharmaceutical company shared topline data from the KYSA-8 Phase 2 trial of mivocabtagene autoleucel (miv-cel, formerly KYV-101) in stiff person syndrome (SPS).

Miv-cel is a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation.

Kyverna Therapeutics shares jumped 31% to $11.49 on Monday.

Here are some other big stocks recording gains in today’s session.

  • Beneficient (NASDAQ:BENF) gained 29.3% to $6.21.
  • Immunome Inc (NASDAQ:IMNM) surged 25.5% to $24.56 after announcing positive topline results from Phase 3 RINGSIDE trial of Varegacestat in patients with Desmoid Tumors.
  • Falcon’s Beyond Global Inc (NASDAQ:FBYD) gained 14% to $12.83.
  • XBP Global Holdings Inc (NASDAQ:XBP) surged 11.5% to $6.39.
  • Almonty Industries Inc (NASDAQ:ALM) gained 9.1% to $7.38 as the company announced voluntary withdrawal of base shelf prospectus and registration statement.
  • Ur-Energy Inc (NYSE:URG) gained 8.6% to $1.39.
  • NovaBay Pharmaceuticals Inc (NYSE:NBY) shares jumped 7.1% to $3.00.
  • AXT Inc (NASDAQ:AXTI) rose 7.1% to $15.88.
  • Olema Pharmaceuticals Inc (NASDAQ:OLMA) jumped 6.8% to $35.30.
  • Silvercorp Metals Inc (NYSE:SVM) gained 6.4% to $8.65.
  • Standard Lithium Ltd (NYSE:SLI) surged 6.3% to $4.91.
  • ZIM Integrated Shipping Services Ltd (NYSE:ZIM) gained 4.8% to $19.64.

Read This Next:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.